The Oxidative Stress State in Diabetes Mellitus Type 2 Patients with Different Medications Types

Subject Areas : Journal of Chemical Health Risks

Israa Harjan Mohsen ¹ ( Departmet of Nursing, Babylon University, College of Nursing, Iraq )
Mohammed Abed Jawad ² ( Department of Medical Laboratory Technology, Al-Nisour University College, Iraq )
Abed J. Kadhim ³ ( Department of Medical Laboratory Technology, Al-Nisour University College, Iraq )
Mona N. Al-Terehi ⁴ ( Department of Biology/Biotechnology, Babylon University, College of Science, Iraq )

Received: 2021-01-12 Accepted : 2021-03-25 Published : 2022-09-01

Keywords:

References:

1. Ceriello A., Motz E., 2004. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 24, 816–23. 


2. Maddux B.A., See W., Lawrence Jr J.C., Goldfine A.L., Goldfine I.D., Evans, J.L., 2001. Protection against oxidative stress—induced insulin resistance in rat L6 muscle cells by micromolar concentrations of α-lipoic acid. Diabetes. 50(2), 404-410.


3. Hirsh I.B., 2005. Intensifying insulin therapy in patients with type 2 diabetes mellitus. Am J Med. 118(Suppl. 5A), 21S–6S. 


4. Vaidyanathan J., Choe S., Sahajwalla C.G., 2012. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. Journal of Pharmaceutical Sciences. 101(5), 1659–1671. 


5. TODAY Study Group, 2012. A clinical trial to maintain glycemic control in youth with type 2 diabetes. New England Journal of Medicine. 366(24), 2247-2256.


6. Jan S.A., Habib N., Shinwari Z.K., Ali M., Ali N., 2021. The anti-diabetic activities of natural sweetener plant Stevia: an updated review. SN Appl. Sci. 3(4), 1-6.


7. Rosenbloom A.L., Silverstein J.H., Amemiya S., Zeitler P., Klingensmith G.J., 2008. ISPAD Clinical Practice Consensus Guidelines 2006–2007. Type 2 diabetes mellitus in the child and adolescent. Pediatric Diabetes. 9(5), 512 526. 

 

 

8. Nathan D.M., Buse J.B., Davidson M.B., 2009. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 52, 17–30.


9. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., Zinman B., 2009. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32(1), 193-203.


10. Fujioka K., Brazg R.L., Raz I., Bruce S., Joyal S., Swanink R., Pans M., 2005. Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies. Diabetes, Obesity and Metabolism. 7(1), 28-39.


11. Akhileshwar V., Patel S.P., Katyare S.S., 2007. Diabetic cardiomyopathy and reactive oxygen species (ROS) related parameters in male and female rats: a comparative study. Indian Journal of Clinical Biochemistry. 22(1), 84-90.


12. Meyer L., Bohme P., Delbachian I., Lehert P., Cugnardey N., Drouin P., Guerci B., 2002. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care. 25(12), 2153-2158.


13. Ajami M., Seyfi M., Hosseini F.A.P., Naseri P., Velayati A., Mahmoudnia F., Zahedirad M., Hajifaraji M., 2020. Effects of stevia on glycemic and lipid profile of type 2 diabetic patients: A randomized controlled trial. Avicenna journal of Phytomedicine. 10(2), 118.